Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.22
−$0.05 · -1.53%
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Previous close
$3.22
−$0.05 · -1.53%
After-hours
$3.22
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Day range
Current $3.22
52-week range
Current $3.22
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
44
Mixed
Risk
63
High Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Day range
Current $3.22
52-week range
Current $3.22
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
210.56% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 21, 2022 | 1:8 | — | — |
Effective Jun 21, 2022
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.41M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM2.76M0.00%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2.43M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO895.38K0.00%18B USD0.06%$112.1-0.10%
iShares Russell 2000 Growth ETFIWO726.39K0.01%14.04B USD0.24%$353.47-0.53%
iShares Micro-Cap ETFIWC374.83K0.03%1.32B USD0.60%$182.79-0.31%
Vanguard Russell 2000 Growth ETFVTWG116.06K0.01%1.7B USD0.06%$258.14-0.44%
Invesco NASDAQ Future Gen 200 ETFQQQS85.5K0.38%22.71M USD0.20%$41.5683-1.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGInvesco NASDAQ Future Gen 200 ETFQQQSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
